Transcriptome level analysis in Rett syndrome using human samples from different tissues.
KeywordsMethyl-Cpg-binding protein 2
MetadataShow full item record
PublisherOrphanet Journal of Rare Diseases
JournalOrphanet Journal of Rare Diseases
AbstractThe mechanisms of neuro-genetic disorders have been mostly investigated in the brain, however, for some pathologies, transcriptomic analysis in multiple tissues represent an opportunity and a challenge to understand the consequences of the genetic mutation. This is the case for Rett Syndrome (RTT): a neurodevelopmental disorder predominantly affecting females that is characterised by a loss of purposeful movements and language accompanied by gait abnormalities and hand stereotypies. Although the genetic aetiology is largely associated to Methyl CpG binding protein 2 (MECP2) mutations, linking the pathophysiology of RTT and its clinical symptoms to direct molecular mechanisms has been difficult. One approach used to study the consequences of MECP2 dysfunction in patients, is to perform transcriptomic analysis in tissues derived from RTT patients or Induced Pluripotent Stem cells. The growing affordability and efficiency of this approach has led to a far greater understanding of the complexities of RTT syndrome but is also raised questions about previously held convictions such as the regulatory role of MECP2, the effects of different molecular mechanisms in different tissues and role of X Chromosome Inactivation in RTT. In this review we consider the results of a number of different transcriptomic analyses in different patients-derived preparations to unveil specific trends in differential gene expression across the studies. Although the analyses present limitations- such as the limited sample size- overlaps exist across these studies, and they report dysregulations in three main categories: dendritic connectivity and synapse maturation, mitochondrial dysfunction, and glial cell activity. These observations have a direct application to the disorder and give insights on the altered mechanisms in RTT, with implications on potential diagnostic criteria and treatments.
SponsorsSS salary was partially supported by Meath Foundation research grant 2015 to L. Gallagher and D. Tropea.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States
- The relationship of Rett syndrome and MECP2 disorders to autism.
- Authors: Neul JL
- Issue date: 2012 Sep
- Transcriptional regulation in pluripotent stem cells by methyl CpG-binding protein 2 (MeCP2).
- Authors: Tanaka Y, Kim KY, Zhong M, Pan X, Weissman SM, Park IH
- Issue date: 2014 Feb 15
- Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation.
- Authors: Cheung AY, Horvath LM, Grafodatskaya D, Pasceri P, Weksberg R, Hotta A, Carrel L, Ellis J
- Issue date: 2011 Jun 1
- MECP2 mutations and clinical correlations in Greek children with Rett syndrome and associated neurodevelopmental disorders.
- Authors: Psoni S, Sofocleous C, Traeger-Synodinos J, Kitsiou-Tzeli S, Kanavakis E, Fryssira-Kanioura H
- Issue date: 2012 Jun
- Exploring the possible link between MeCP2 and oxidative stress in Rett syndrome.
- Authors: Filosa S, Pecorelli A, D'Esposito M, Valacchi G, Hajek J
- Issue date: 2015 Nov